Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1324-1328 , June 2010

The activation of p38alpha, and not p38beta, mitogen-activated protein kinase is required for ischemic preconditioning

  • Pierre Sicard

      Affiliations

    • King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK
    • ,
  • James E. Clark

      Affiliations

    • King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK
    • ,
  • Sebastien Jacquet

      Affiliations

    • King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK
    • ,
  • Shahrooz Mohammadi

      Affiliations

    • King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK
    • ,
  • J. Simon C. Arthur

      Affiliations

    • MRC Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
    • ,
  • Stephen J. O'Keefe

      Affiliations

    • Department of Immunology, Merck Research Laboratories, Rahway, NJ 07065, USA
    • ,
  • Michael S. Marber

      Affiliations

    • King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7188 1008; fax: +44 20 7188 0970.

Received 1 February 2010 ,Revised 16 February 2010 ,Accepted 17 February 2010.

References 

  1. Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther. 2007;116:192–206
  2. Sanada S, Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res. 2001;88:175–180
  3. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS. Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res. 2001;89:750–752
  4. Eyers PA, van d I, Quinlan RA, Goedert M, Cohen P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 1999;451:191–196
  5. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A. 2003;100:15434–15439
  6. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, et al. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 2000;14:2237–2246
  7. Wang Y, Huang S, Sah VP, Ross J, Brown JH, Han J, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161–2168
  8. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y, et al. Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem. 2005;280:669–676
  9. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia–reperfusion in vivo. J Biol Chem. 2004;279:15524–15530
  10. Otsu K, Yamashita N, Nishida K, Hirotani S, Yamaguchi O, Watanabe T, et al. Disruption of a single copy of the p38alpha MAP kinase gene leads to cardioprotection against ischemia–reperfusion. Biochem Biophys Res Commun. 2003;302:56–60
  11. O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, et al. Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. J Biol Chem. 2007;282:34663–34671
  12. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol. 2005;25:10454–10464
  13. Kumphune S, Bassi R, Jacquet S, Sicard P, Clark JE, Verma S, et al. A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580. J Biol Chem. 2010;285:2968–2975
  14. Cook SA, Clerk A, Sugden PH. Are transgenic mice the ‘alkahest’ to understanding myocardial hypertrophy and failure?. J Mol Cell Cardiol. 2009;46:118–129
  15. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, Watanabe T, et al. p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol. 2004;24:10611–10620
  16. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol. 2006;6:532–540

PII: S0022-2828(10)00074-X

doi: 10.1016/j.yjmcc.2010.02.013

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1324-1328 , June 2010

Article Tools

* Image Usage & Resolution